Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease
Study limitation reported by the research below: “The nonrandomized design means observed changes in biomarkers cannot be confidently attributed to psilocybin rather than other factors such as disease progression or regression to the mean.”